293 related articles for article (PubMed ID: 27601506)
1. A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
Haslem DS; Van Norman SB; Fulde G; Knighton AJ; Belnap T; Butler AM; Rhagunath S; Newman D; Gilbert H; Tudor BP; Lin K; Stone GR; Loughmiller DL; Mishra PJ; Srivastava R; Ford JM; Nadauld LD
J Oncol Pract; 2017 Feb; 13(2):e108-e119. PubMed ID: 27601506
[TBL] [Abstract][Full Text] [Related]
2. Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.
Haslem DS; Chakravarty I; Fulde G; Gilbert H; Tudor BP; Lin K; Ford JM; Nadauld LD
Oncotarget; 2018 Feb; 9(15):12316-12322. PubMed ID: 29552312
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
4. The value proposition of molecular medicine.
Waldman SA; Terzic A
Clin Transl Sci; 2012 Feb; 5(1):108-10. PubMed ID: 22376267
[No Abstract] [Full Text] [Related]
5. Clinical and cost outcomes following genomics-informed treatment for advanced cancers.
Weymann D; Pollard S; Chan B; Titmuss E; Bohm A; Laskin J; Jones SJM; Pleasance E; Nelson J; Fok A; Lim H; Karsan A; Renouf DJ; Schrader KA; Sun S; Yip S; Schaeffer DF; Marra MA; Regier DA
Cancer Med; 2021 Aug; 10(15):5131-5140. PubMed ID: 34152087
[TBL] [Abstract][Full Text] [Related]
6. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
7. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
8. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
10. The financial hazard of personalized medicine and supportive care.
Carrera PM; Olver I
Support Care Cancer; 2015 Dec; 23(12):3399-401. PubMed ID: 26306523
[TBL] [Abstract][Full Text] [Related]
11. Association of Integrated Team-Based Care With Health Care Quality, Utilization, and Cost.
Reiss-Brennan B; Brunisholz KD; Dredge C; Briot P; Grazier K; Wilcox A; Savitz L; James B
JAMA; 2016 Aug 23-30; 316(8):826-34. PubMed ID: 27552616
[TBL] [Abstract][Full Text] [Related]
12. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB; Pisters-van Roy A; van Saase L; van der Graaff M; Gijzen J; Sleijfer S; Hoes LR; van Berge Henegouwen JM; van der Wijngaart H; van der Velden DL; van Werkhoven E; Retel VP; van Harten WH; Huitema ADR; Timmers L; Gelderblom H; Verheul HMW; Voest EE
Ann Oncol; 2019 May; 30(5):663-665. PubMed ID: 31038154
[No Abstract] [Full Text] [Related]
13. Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?
Fernandes GS; Marques DF; Girardi DM; Braghiroli MIF; Coudry RA; Meireles SI; Katz A; Hoff PM
Clinics (Sao Paulo); 2017 Oct; 72(10):588-594. PubMed ID: 29160420
[TBL] [Abstract][Full Text] [Related]
14. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
15. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine.
Damodaran S; Berger MF; Roychowdhury S
Am Soc Clin Oncol Educ Book; 2015; ():e175-82. PubMed ID: 25993170
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
[TBL] [Abstract][Full Text] [Related]
17. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
18. Costs Cast Shadow on Optimism about Treatment.
Manag Care; 2016 Oct; 25(10):29. PubMed ID: 28121542
[TBL] [Abstract][Full Text] [Related]
19. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
[TBL] [Abstract][Full Text] [Related]
20. Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.
Zemni I; Ghalleb M; Jbir I; Slimane M; Ben Hassouna J; Ben Dhieb T; Bouzaiene H; Rahal K
World J Surg Oncol; 2017 Nov; 15(1):206. PubMed ID: 29169398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]